⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
JUNS News
Jupiter Neurosciences, Inc. Common Stock
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
accessnewswire.com
COE
ACCS
ASNS
DRTS
AREB
BKYI
FUFU
CJMB
DVLT
FBLG
MEHA
HCTI
INDO
JUNS
KAPA
LIXT
MYSZ
NNVC
HOVR
NOMA
OPTT
OWLS
PERF
PHIO
PROP
PRPO
SJ
LITM
SOPA
SNGX
XHLD
TYGO
TIVC
TRX
WGRX
WWR
ZENA
FLGC
Kaskela Law Firm Announces Stockholder Investigation of Jupiter Neurosciences, Inc. (NASDAQ:JUNS) and Encourages Long-Term JUNS Investors to Contact the Firm
accessnewswire.com
JUNS
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
globenewswire.com
JUNS
SHAREHOLDER ALERT: Kaskela Law Firm Announces Investigation of Jupiter Neurosciences, Inc. (JUNS) And Encourages Current JUNS Shareholders to Contact The Firm
accessnewswire.com
JUNS
Toripalimab Presents Long-Term Survival Benefits as 1st-line Treatment for Advanced Nasopharyngeal Carcinoma and Esophageal Squamous Cell Carcinoma Patients
globenewswire.com
JUNS
Junshi Biosciences Announces Acceptance of the NDA for Roconkibart (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis
globenewswire.com
JUNS
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
globenewswire.com
JUNS
Jupiter Neurosciences to Participate in NobleCon21
newsfilecorp.com
JUNS
Junshi Biosciences Announces Primary Endpoints Met in JS001sc’s Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC
globenewswire.com
JUNS
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
globenewswire.com
JUNS